Table 2.

Features associated with presenting with polyarthritis vs oligoarthritis based on all patientsa.

CovariateUnivariate AnalysisMultivariate Analysis
Full ModelReduced Model
OR (95% CI)POR (95% CI)POR (95% CI)P
Age, yrs1.02 (0.99–1.04)0.201.02 (0.99–1.04)0.13
PsA duration, yrs1.42 (0.88–2.32)0.151.41 (0.89–2.21)0.14
Sex (M vs F)0.81 (0.44–1.51)0.530.93 (0.51–1.69)0.80
LE SJ13.52 (8.30–22.03)< 0.00117.80 (9.17–34.55)< 0.00117.15 (9.04–32.56)< 0.001
UE SJ9.93 (6.00–16.44)< 0.00117.10 (8.24–35.50)< 0.00115.69 (7.72–31.89)< 0.001
LE LJ3.87 (2.48–6.02)< 0.0013.49 (1.75–6.95)< 0.0013.71 (1.87–7.37)< 0.001
UE LJ5.03 (3.20–7.90)< 0.0015.14 (2.62–10.08)< 0.0014.71 (2.45–9.03)< 0.001
Enthesitis2.12 (1.30–3.46)0.0031.62 (0.76–3.45)0.21
PASI1.02 (0.99–1.04)0.181.03 (0.99–1.07)0.19
Highest medication
      NSAIDs0.74 (0.47–1.16)0.190.62 (0.31–1.20)0.16
      DMARDs1.14 (0.64–2.05)0.651.37 (0.52–3.61)0.52
      Biologics0.57 (0.22–1.49)0.250.65 (0.15–2.89)0.57
  • aBased on 407 patients with only the covariate information available at baseline clinic visit (215 with polyarthritis, 192 with oligoarthritis). DMARD: disease-modifying antirheumatic drug; LE: lower extremity; LJ: large joint; NSAID: nonsteroidal antiinflammatory drugs; PASI: Psoriasis Area Severity Index; PsA: psoriatic arthritis; SJ: small joint; UE: upper extremity.